Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Azithromycin for Symptomatic Meibomian Gland Disease
NCT03953118Phase 4Terminated
- Sponsor
- University of California, San Francisco
- Start
- Sep 2019
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in meibomian gland dysfunction (MGD) and dry eye syndrome (DED) comparing Azithromycin with Placebo (2 arms). Primary endpoint: Ocular Surface Disease Index Questionnaire at 3 months. Started Sep 2019; status: terminated.
02
Drugs
azithromycin
03
Conditions
meibomian gland dysfunction (MGD)dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT03953118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03953118.